drugset / Trial / NCT02600390

SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer

NCT02600390

Phase 2 Completed 10 enrolled Prolong Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

SANGUINATE™ Sickle Cell Disease associated Leg Ulcers.

Timeline

Start
2016-03
Primary completion
2016-10
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject pegylated carboxyhemoglobin bovine Protein / enzyme biologic 8 ml Intravenous
Subject pegylated carboxyhemoglobin bovine Protein / enzyme biologic 320 mg/kg Intravenous

Indications